Advertisement

Topics

Dementia Associated With Alzheimer's Disease Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $1250

19:24 EDT 18 Aug 2017 | BioPortfolio Reports

DelveInsight's, Dementia Associated With Alzheimer's Disease Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Dementia Associated With Alzheimer's Disease. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Dementia Associated With Alzheimer's Disease. This report provides information on the therapeutic development for Dementia Associated With Alzheimer's Disease, dealing with all the pipeline drugs and comparative analysis at various stages covering all clinical, preclinical as well as discovery products. The report further contains details on dormant products and discontinued products. Therapeutic assessment of all the active products by route of administration and molecule type is also covered in this report.
The report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and nonprintable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Otsuka Pharmaceutical Co. Ltd.; Eli lilly company; Novartis Forest Laboratories; Adamas Pharmaceuticals Inc.; AgeneBio Inc.; Amarantus Bioscience Holdings Inc.; Boehringer Ingelheim GmbH; Chase Pharmaceuticals Corporation; Eisai Co. Ltd; H. Lundbeck A/S; MediPost Co. Ltd.
Dementia Associated With Alzheimer's Disease Pipeline Drugs
Dementia Associated With Alzheimer's Disease Pipeline Assessment
Dementia Associated With Alzheimer's Disease Pipeline Analysis
Dementia Associated With Alzheimer's Disease Drugs under Development
Dementia Associated With Alzheimer's Disease Discovery drugs
Dementia Associated With Alzheimer's Disease Preclinical drugs
Dementia Associated With Alzheimer's Disease Phase I drugs
Dementia Associated With Alzheimer's Disease Phase II drugs
Dementia Associated With Alzheimer's Disease Phase III Pipeline Drugs Assessment
Dementia Associated With Alzheimer's Disease Preregistration drugs
Dementia Associated With Alzheimer's Disease Molecules in pipeline

Original Article: Dementia Associated With Alzheimer's Disease Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $1250

NEXT ARTICLE

More From BioPortfolio on "Dementia Associated With Alzheimer's Disease Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $1250"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Dementia
Dementia describes a range of symptoms of cognitive decline. For example memory loss, problems with reasoning and communication skills, and a reduction in a person's abilities and skills in carrying out daily activities. There are about 820,000 peo...